Abstract
Objective: This study aims to evaluate the blood pressure and heart rates of the patients treated with aripiprazole once-monthly,
paliperidone 1-month, and paliperidone 3-month long-acting injections.
Patients and Methods: This study was a non-invasive observational study. Subjects using the same long-acting injection preparation
for at least four months without skipped injections were assigned to 3 groups according to their treatments. They were screened
starting from routine injection day and monthly for four months. Heart rate, systolic blood pressure, and diastolic blood pressure were
recorded for each subject.
Results: Systolic and diastolic blood pressure among the three treatment groups demonstrated no statistical significance. The heart rate
of the paliperidone 3-month group was significantly higher than the aripiprazole once-monthly group. However, the mean heart rate
was within the physiological limits. Thus, a clinical significance can hardly be attributed.
Conclusion: Aripiprazole once-monthly, paliperidone 1-month, and paliperidone 3-month long-acting injections are non-inferior
regarding heart rate, systolic and diastolic blood pressure during the maintenance treatment.
Reference35 articles.
1. [1] Simeone JC, Ward AJ, Rotella P, Collins J, Windisch R.
An evaluation of variation in published estimates of
schizophrenia prevalence from 1990-2013: A systematic
literature review. BMC Psychiatry 2015; 15:193. doi: 10.1186/
s12888.015.0578-7
2. [2] Taylor DM, Barnes TR, Young AH. The Maudsley Prescribing
Guidelines in Psychiatry. 13th ed. Hoboken, NJ: Wiley-
Blackwell. 2020.
3. [3] Valsecchi P, Barlati S, Garozzo A, et al. Paliperidone palmitate
in short – and long-term treatment of schizophrenia. Riv
Psichiatr 2019; 54:235-48. doi: 10.1708/3281.32542
4. [4] Potkin SG, Preda A. Aripiprazole once-monthly longacting
injectable for the treatment of schizophrenia. Expert
Opin Pharmacother 2016; 17:395-407. doi:
10.1517/14656.566.2015.1114100
5. [5] Kane JM, Sanchez R, Perry PP, et al. Aripiprazole intramuscular
depot as maintenance treatment in patients with schizophrenia:
A 52-week, multicenter, randomized, double-blind, placebocontrolled
study. J Clin Psychiatry 2012; 73:617-24. doi:
10.4088/JCP.11m07530